Cargando…

No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications

SUMMARY: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurunluoglu, Raffi, Kubek, Eddie, Arton, Jamie, Olsen, Adam, Bronsert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174107/
https://www.ncbi.nlm.nih.gov/pubmed/25289281
http://dx.doi.org/10.1097/GOX.0000000000000027
_version_ 1782336302654423040
author Gurunluoglu, Raffi
Kubek, Eddie
Arton, Jamie
Olsen, Adam
Bronsert, Michael
author_facet Gurunluoglu, Raffi
Kubek, Eddie
Arton, Jamie
Olsen, Adam
Bronsert, Michael
author_sort Gurunluoglu, Raffi
collection PubMed
description SUMMARY: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Thus, there is a chance that any reexcision after a shave biopsy which is positive for BCC may be negative for tumor. This finding substantiates our realization that sometimes what some would call unnecessary surgery is a common reality. The surgeon’s goal is tumor eradication, and therefore, watchful waiting is usually not a legitimate clinical implication. This report has value in letting our esteemed legal colleagues know what we do not know, which still remains within the standard of appropriate care. However, the finding of no residual tumor in the current report may change our practice habits. Watchful waiting may be an option, particularly in the elderly and fragile patients. Also, one may opt to decrease the safety margins during excision when treating patients with biopsy-proven BCC. However, reconstructive procedures may still be required in the case of nonpersistent tumor. Therefore, it is extremely important that the informed consent should include statements regarding possible reconstructive procedures to avoid medicolegal implications.
format Online
Article
Text
id pubmed-4174107
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-41741072014-10-06 No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications Gurunluoglu, Raffi Kubek, Eddie Arton, Jamie Olsen, Adam Bronsert, Michael Plast Reconstr Surg Glob Open Special Topic SUMMARY: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Thus, there is a chance that any reexcision after a shave biopsy which is positive for BCC may be negative for tumor. This finding substantiates our realization that sometimes what some would call unnecessary surgery is a common reality. The surgeon’s goal is tumor eradication, and therefore, watchful waiting is usually not a legitimate clinical implication. This report has value in letting our esteemed legal colleagues know what we do not know, which still remains within the standard of appropriate care. However, the finding of no residual tumor in the current report may change our practice habits. Watchful waiting may be an option, particularly in the elderly and fragile patients. Also, one may opt to decrease the safety margins during excision when treating patients with biopsy-proven BCC. However, reconstructive procedures may still be required in the case of nonpersistent tumor. Therefore, it is extremely important that the informed consent should include statements regarding possible reconstructive procedures to avoid medicolegal implications. Wolters Kluwer Health 2014-01-06 /pmc/articles/PMC4174107/ /pubmed/25289281 http://dx.doi.org/10.1097/GOX.0000000000000027 Text en Copyright © 2013 The Authors. Published by Lippincott Williams & Wilkins on behalf of The American Society of Plastic Surgeons. PRS Global Open is a publication of the American Society of Plastic Surgeons. http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Special Topic
Gurunluoglu, Raffi
Kubek, Eddie
Arton, Jamie
Olsen, Adam
Bronsert, Michael
No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_full No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_fullStr No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_full_unstemmed No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_short No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_sort no residual basal cell carcinoma after excision for biopsy-proven tumor: clinical and medicolegal implications
topic Special Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174107/
https://www.ncbi.nlm.nih.gov/pubmed/25289281
http://dx.doi.org/10.1097/GOX.0000000000000027
work_keys_str_mv AT gurunluogluraffi noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT kubekeddie noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT artonjamie noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT olsenadam noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT bronsertmichael noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications